<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085409" disease_type="Disease or Syndrome" abbrv="">Autoimmune polyglandular syndrome</z:e> (APS) type 2 (<z:e sem="disease" ids="C0085860" disease_type="Disease or Syndrome" abbrv="">Schmidt syndrome</z:e>) is a disorder characterized by a combination of autoimmune <z:hpo ids='HP_0000846'>adrenal insufficiency</z:hpo>, autoimmune <z:hpo ids='HP_0000820'>thyroid disease</z:hpo>, and type 1 autoimmune <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We describe the first case of <z:hpo ids='HP_0011011'>subacute</z:hpo> <z:e sem="disease" ids="C0007760" disease_type="Disease or Syndrome" abbrv="">cerebellar syndrome</z:e> associated with APS type 2 </plain></SENT>
<SENT sid="2" pm="."><plain>Brain magnetic resonance imaging showed <z:mpath ids='MPATH_127'>atrophy</z:mpath> of the cerebellum and the vermis, as well as of the anterior pituitary gland </plain></SENT>
<SENT sid="3" pm="."><plain>Magnetic resonance spectroscopy showed decreased N-acetylaspartate/<z:chebi fb="2" ids="16919">creatine</z:chebi> ratio in the cerebellum and in the pons </plain></SENT>
<SENT sid="4" pm="."><plain>Our findings expand the spectrum of neurological deficits in APS type 2 and underlines that cerebellar pathways may be a main target of the disorder </plain></SENT>
</text></document>